A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.American journal of hematology · 2012
   Trial
2. The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies.Vaccines · 2023
   Review
3. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.Frontiers in immunology · 2023
   Review
4. miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
   Article
5. Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands.BioImpacts : BI · 2022
   Review
6. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.European journal of medicinal chemistry · 2020
   Review
7. Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Frontiers in pharmacology · 2017
   Review
8. Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
   Observational
9. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.Journal of immunology (Baltimore, Md. : 1950) · 2015
   Article
10. Toll-like receptors in the pathogenesis of human B cell malignancies.Journal of hematology & oncology · 2014
    Review
11. Toll-like Receptors in Chronic Lymphocytic Leukemia.Mediterranean journal of hematology and infectious diseases · 2012
    Article
12. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.Leukemia · 2011
    Article
13. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Expert review of clinical pharmacology · 2011
    Review
14. Important aspects of Toll-like receptors, ligands and their signaling pathways.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010
    Review
15. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia.Leukemia · 2010
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as